Maze Therapeutics (MAZE) Net Cash Flow (2024 - 2026)

Maze Therapeutics (MAZE) has 3 years of Net Cash Flow data on file, last reported at $9.5 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 90.24% year-over-year to $9.5 million; the trailing twelve-month figure through Mar 2026 stood at -$95.6 million (down 136.17% YoY), and the FY2025 full-year result was -$7.6 million, down 104.51% from the prior year.
• Net Cash Flow climbed to $9.5 million in Q1 2026, from -$127.5 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $145.0 million in Q2 2024 to a low of -$127.5 million in Q4 2025.
• A 3-year average of $18.8 million and a median of $9.5 million in 2026 frame the typical range for Net Cash Flow.
• Peak annual rise in Net Cash Flow reached 11178.96% in 2025, while the deepest fall reached 370.16% in 2025.
• Tracing MAZE's Net Cash Flow over 3 years: stood at $47.2 million in 2024, then sank by 370.16% to -$127.5 million in 2025, then jumped by 107.46% to $9.5 million in 2026.
• Business Quant data shows MAZE's Net Cash Flow at $9.5 million in Q1 2026, -$127.5 million in Q4 2025, and $52.2 million in Q3 2025.